Godavari Drugs Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 124.95 as of 05 May 15:30 . The P/E Ratio of Godavari Drugs Ltd changed from 8.4 on March 2021 to 15 on March 2025 . This represents a CAGR of 12.30% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 37.1 on March 2021 to 99.3 on March 2025 . This represents a CAGR of 21.76% over 5 years The Market Cap of Godavari Drugs Ltd changed from ₹ 34.45 crore on March 2021 to ₹ 65.86 crore on March 2025 . This represents a CAGR of 13.84% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 6.97 crore on March 2021 to ₹ 956.77 crore on March 2025 . This represents a CAGR of 167.62% over 5 years The revenue of Godavari Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Godavari Drugs Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Godavari Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of 0.0% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 5 quarters. This represents a CAGR of 343.89% The Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Godavari Drugs Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Godavari Drugs Ltd is 126 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,402 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd?

As of May 5, 2026, the Godavari Drugs Ltd stock price is INR ₹124.95. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹32.02.

How do dividend payouts of Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.